13F Holdings
中文EN

VTRS Viatris Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1792044 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY4.3%
TTM net income YoY—
TTM EPS YoY83.1%
Revenue 3-yr CAGR-1.6%
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-0.0%
Net margin—
FCF margin14.3%
EBITDA margin19.1%

Returns

ROE—
ROA—
ROIC (approx.)-0.0%
Asset turnover0.41x

Leverage & solvency

Liabilities / assets60.5%
Debt / equity0.97x
Current ratio1.55x
Interest coverage-0.01x

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue$14.30B$14.74B$15.43B$16.26B$17.89B
Cost of revenue$9.29B$9.12B$8.99B$9.77B$12.31B
Gross profit$5.01B$5.62B$6.44B$6.50B$5.58B
R&D expense$965.90M$808.70M$805.20M$662.20M$681.00M
SG&A expense$3.79B$4.10B$4.07B$4.18B$4.53B
Operating income-$2.66B$10.10M$766.20M$1.61B-$34.00M
Interest expense$471.30M$550.00M$573.10M$592.40M$636.20M
Pretax income-$3.67B-$623.20M$202.90M$2.81B-$664.40M
Income tax-$150.10M$11.00M$148.20M$734.60M$604.70M
Net income-$3.51B-$634.20M$54.70M$2.08B-$1.27B
EBITDA$135.20M$2.90B$3.51B$4.64B$4.47B
EPS (basic)-3.00-0.530.051.71-1.05
EPS (diluted)-3.00-0.530.051.71-1.05
Dividends declared per share0.480.480.480.480.33
Weighted avg. shares (diluted)——1.21B1.22B1.21B
Balance sheet
Cash & equivalents$1.32B$736.10M$991.90M$1.26B$706.20M
Short-term investments$40.70M$38.00M$37.00M$35.30M$38.20M
Receivables$3.03B$3.22B$3.70B$3.81B$4.27B
Inventory$4.00B$3.85B$3.47B$3.52B$3.98B
Current assets$9.79B$9.52B$12.98B$10.64B$10.90B
PP&E, net$2.61B$2.67B$2.76B$3.02B$3.19B
Goodwill$6.75B$9.13B$9.87B$10.43B$12.11B
Intangibles$15.10B$17.07B$19.18B$22.61B$26.13B
Total assets$37.19B$41.50B$47.69B$50.02B$54.84B
Current liabilities$7.09B$5.78B$7.78B$6.75B$9.88B
Short-term debt$1.93B$600,000$1.93B$1.25B$1.86B
Long-term debt$12.48B$14.04B$16.19B$18.02B$19.72B
Total debt$14.41B$14.04B$18.12B$19.27B$21.58B
Total liabilities$22.48B$22.87B$27.22B$28.95B$34.35B
Shareholders' equity$14.71B$18.64B$20.47B$21.07B$20.49B
Net debt$13.09B$13.30B$17.13B$18.00B$20.87B
Cash flow statement
Operating cash flow$2.32B$2.30B$2.90B$3.00B$3.02B
Capital expenditure$378.80M$326.00M$377.00M$406.00M$457.20M
Free cash flow$1.94B$1.98B$2.52B$2.59B$2.56B
Investing cash flow-$427.70M$1.80B-$864.50M$1.47B-$117.80M
Financing cash flow-$1.29B-$4.33B-$2.30B-$3.88B-$3.01B
Depreciation & amortization$2.80B$2.89B$2.74B$3.03B$4.51B
Stock-based compensation$177.70M$146.10M$180.70M$116.40M$111.20M
Share buybacks$500.50M$250.00M$250.00M$0$0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.